INSULET CORP's ticker is PODD and the CUSIP is 45784P101. A total of 589 filers reported holding INSULET CORP in Q2 2024. The put-call ratio across all filers is 2.00 and the average weighting 0.1%.
About INSULET CORP
Insulet Corp is a medical device company that specializes in the development and manufacturing of insulin delivery systems for people with diabetes. The company's flagship product, the Omnipod Insulin Management System, is a tubeless, waterproof insulin pump that provides continuous insulin delivery for up to three days.
Insulet Corp has been making waves in the diabetes community with its innovative approach to insulin delivery. The Omnipod system is a game-changer for people with diabetes who are tired of the hassle and discomfort of traditional insulin pumps. The tubeless design allows for greater freedom of movement and eliminates the need for tubing, which can be cumbersome and uncomfortable.
The company has also been expanding its product line with the recent launch of the Omnipod DASH system, which features a touchscreen controller and Bluetooth connectivity for remote monitoring. This new system is expected to further improve the user experience for people with diabetes.
Insulet Corp has been experiencing steady growth in recent years, with revenue increasing by 29% in 2020. The company's success can be attributed to its focus on innovation and commitment to improving the lives of people with diabetes.
Overall, Insulet Corp is a company to watch in the medical device industry. Its innovative approach to insulin delivery has the potential to revolutionize the way people with diabetes manage their condition, and its commitment to improving the user experience is sure to win over even more customers in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,741,133 | +43.5% | 48,271 | +21.9% | 0.07% | +45.8% |
| Q1 2024 | $6,786,583 | +3.7% | 39,595 | +31.2% | 0.05% | -7.7% |
| Q4 2023 | $6,546,070 | +173.0% | 30,169 | +100.7% | 0.05% | +147.6% |
| Q3 2023 | $2,397,932 | -36.2% | 15,035 | +15.4% | 0.02% | -36.4% |
| Q2 2023 | $3,756,782 | -3.3% | 13,029 | +7.0% | 0.03% | -8.3% |
| Q1 2023 | $3,884,295 | +11.0% | 12,178 | +2.4% | 0.04% | +2.9% |
| Q4 2022 | $3,499,414 | +52.5% | 11,887 | +18.9% | 0.04% | +40.0% |
| Q3 2022 | $2,294,000 | +33.8% | 10,000 | +27.1% | 0.02% | +56.2% |
| Q2 2022 | $1,714,000 | -12.1% | 7,865 | +7.4% | 0.02% | -5.9% |
| Q1 2022 | $1,951,000 | +14.0% | 7,323 | +13.8% | 0.02% | +30.8% |
| Q4 2021 | $1,712,000 | -1.6% | 6,435 | +5.2% | 0.01% | -7.1% |
| Q3 2021 | $1,739,000 | +5.6% | 6,117 | +2.0% | 0.01% | 0.0% |
| Q2 2021 | $1,647,000 | +6.5% | 5,998 | +1.2% | 0.01% | 0.0% |
| Q1 2021 | $1,546,000 | +28.3% | 5,927 | +25.7% | 0.01% | +27.3% |
| Q4 2020 | $1,205,000 | – | 4,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 264,041 | $53,283,474 | 5.42% |
| Parkman Healthcare Partners LLC | 179,305 | $36,183,749 | 4.85% |
| First Light Asset Management, LLC | 215,637 | $43,515,547 | 3.82% |
| Beck Bode, LLC | 93,187 | $18,805,118 | 3.78% |
| AMI ASSET MANAGEMENT CORP | 289,420 | $58,405,008 | 3.15% |
| Stanley-Laman Group, Ltd. | 66,681 | $13,456,226 | 1.93% |
| ROSENBLUM SILVERMAN SUTTON S F INC /CA | 34,869 | $7,036,564 | 1.88% |
| Millrace Asset Group, Inc. | 9,535 | $1,924 | 1.87% |
| Sivik Global Healthcare LLC | 25,000 | $5,045 | 1.81% |
| FORMULA GROWTH LTD | 20,865 | $4,210,557 | 1.53% |